Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

G. Robinson, Jennifer; Farnier, Michel; Krempf, Michel; Bergeron, Jean; Luc, Gérald; Averna, Maurizio; S.G. Stroes, Erik; Langslet, Gisle; J. Raal, Frederick; El Shahawy, Mahfouz; J. Koren, Michael; E. Lepor, Norman; Lorenzato, Christelle; Pordy, Robert; Chaudhari, Umesh; J.P. Kastelein, John

doi:10.1056/nejmoa1501031

Public

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

Published in New England Journal of Medicine • Mar 15, 2015

Authors:

Jennifer G. Robinson

Michel Farnier

Michel Krempf

Abstract

BACKGROUND: Alirocumab, a monoclonal antibody that inhibits proprotein convertase subtilisin-kexin type 9 (PCSK9), has been shown to reduce low-density lipoprotein (LDL) cholesterol levels in patients who are receiving statin therapy. Larger and longer-term studies are needed to establish safety and...

Subject

Alirocumab

Medicine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!